%0 Journal Article
%A de la Hera, Belén
%A Urcelay, Elena
%A Brassat, David
%A Chan, Andrew
%A Vidal-Jordana, Angela
%A Salmen, Anke
%A Villar, Luisa Maria
%A Alvarez-Cermeño, José Carlos
%A Izquierdo, Guillermo
%A Fernández, Oscar
%A Oliver, Begoña
%A Saiz, Albert
%A Ara, Jose Ramón
%A Vigo, Ana G
%A Arroyo, Rafael
%A Meca, Virginia
%A Malhotra, Sunny
%A Fissolo, Nicolás
%A Horga, Alejandro
%A Montalban, Xavier
%A Comabella, Manuel
%T Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.
%D 2014
%U http://hdl.handle.net/10668/2175
%X OBJECTIVESWe aimed to investigate potential associations between human leukocyte antigen (HLA) class I and class II alleles and the development of anaphylactic/anaphylactoid reactions in patients with multiple sclerosis (MS) treated with natalizumab.METHODSHLA class I and II genotyping was performed in patients with MS who experienced anaphylactic/anaphylactoid reactions and in patients who did not develop infusion-related allergic reactions following natalizumab administration.RESULTSA total of 119 patients with MS from 3 different cohorts were included in the study: 54 with natalizumab-related anaphylactic/anaphylactoid reactions and 65 without allergic reactions. HLA-DRB1*13 and HLA-DRB1*14 alleles were significantly increased in patients who developed anaphylactic/anaphylactoid reactions (p M-H = 3 × 10(-7); odds ratio [OR]M-H = 8.96, 95% confidence interval [CI] = 3.40-23.64), with a positive predictive value (PPV) of 82%. In contrast, the HLA-DRB1*15 allele was significantly more represented in patients who did not develop anaphylactic/anaphylactoid reactions to natalizumab (p M-H = 6 × 10(-4); ORM-H = 0.2, 95% CI = 0.08-0.50), with a PPV of 81%.CONCLUSIONSHLA-DRB1 genotyping before natalizumab treatment may help neurologists to identify patients with MS at risk for developing serious systemic hypersensitivity reactions associated with natalizumab administration.
%K Alelos
%K Anticuerpos monoclonales humanizados
%K Antígenos de histocompatibilidad clase I
%K Prueba de histocompatibilidad
%K Esclerosis múltiple
%~